N=1 Collaborative

About N=1 Collaborative

In 2018, a groundbreaking event occurred when Mila, a seven-year-old girl diagnosed with a fatal neurogenetic disease, became the first person in the world to receive a drug tailored specifically for her condition. Named milasen, this innovative treatment was developed through an extraordinary collaboration among scientists, physicians, drug developers, foundations, and regulators, all within just one year of her diagnosis. Although Mila ultimately lost her battle, milasen significantly improved her quality of life by suppressing her seizures.

Impact of Individualized Medicine

The publication of this remarkable effort in the New England Journal of Medicine in 2019 marked a pivotal moment in the field of individualized genomic medicine, inspiring hope for patients with rare diseases. Following this success, the N=1 Collaborative was established in 2021 as the first international hub dedicated to advancing individualized medicines for rare diseases. With support from the Oligonucleotide Therapeutics Society N-of-1+ Taskforce and the Chan Zuckerberg Initiative, this collaborative network is committed to developing a standardized framework for individualized treatments.

Why Donate?

Your generous donation to the N=1 Collaborative directly supports the advancement of individualized medicines that can transform the lives of patients suffering from rare genetic diseases. Contributions help foster collaboration among experts and drive critical research efforts.

Join the Movement

Be a part of this revolutionary journey in medicine. Donate cryptocurrency or cash today to support the N=1 Collaborative and help bring hope to patients in need.